🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

403 results for “Institut für biomedizinische Analytik NMR-Imaging GmbH” Clear

  1. Cyclophosphamide Injection 500 mg., Vincristine Sulfate 1 mg/ml solution for injection, Cisplatin 1 mg/ml concentrate for solution for infusion, Temodal 100 mg hard capsules, Etoposide 20 mg/ml Concentrate for Solution for Infusion, Thiotepa 15 mg Powder for solution for injection , Qarziba 4.5 mg/mL concentrate for solution for infusion, Melphalan 50 mg concentrate and solvent for solution for injection/infusion, Busulfan 6 mg/ml concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with High Risk Neuroblastoma

    phase 3 small molecule active

    1 trial

  2. DEXAMETHASONE, CAPECITABINE , OXALIPLATIN , FLUOROURACIL , FOLINIC ACID, METOCLOPRAMIDE, ONDANSETRON

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    locally advanced rectal cancer

    phase 3 small molecule active

    1 trial

  3. DIAMICRON 60MG, comprimé sécable à libération modifiée, Placebo S05762, METFORMIN, Forxiga 10 mg film-coated tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin

    phase 3 small molecule active

    1 trial

  4. Doxycycline Sandoz 100 mg tabletten, Doxycycline EG 200 mg Tabletten

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Sexually Transmitted Infections

    phase 3 small molecule active

    1 trial

  5. EstroTep 500 MBq/mL, solution injectable

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  6. FLORTAUCIPIR (18F), FLORTAUCIPIR (18F), FLORBETAPIR (18F), FLORBETAPIR (18F)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  7. FLUCONAZOLE , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMOXICILLIN , METRONIDAZOLE , CIPROFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CLINDAMYCIN , DOXYCYCLINE , LINEZOLID , SODIUM CHLORIDE SOLUTION 0.9%

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with hip or knee infections

    phase 3 small molecule active

    1 trial

  8. FLUOROURACIL, Tecentriq 1 200 mg concentrate for solution for infusion, CALCIUM FOLINATE PENTAHYDRATE, OXALIPLATIN

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  9. FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, HYDROCHLOROTHIAZIDE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Acute Heart Failure

    phase 3 small molecule active

    1 trial

  10. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Placebo formulation of Gardasil, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.

    phase 3 small molecule active

    1 trial

  11. Grafalon 20 mg/ml concentrato per soluzione per infusione

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    phase 3 small molecule active

    1 trial

  12. HOLOXAN 2000 mg, poudre pour usage parentéral, DETICENE 100 mg, poudre et solvant pour solution pour perfusion, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Resectable, non-metastatic soft-tissue sarcoma (STS)

    phase 3 small molecule active

    1 trial

  13. Humira 40 mg solution for injection in pre-filled syringe, ORENCIA 50 mg solution for injection in pre-filled syringe, Tyenne 162mg/0.9ml solution for injection in pre-filled syringe, Humira 20 mg solution for injection in pre-filled syringe, XELJANZ 1 mg/mL oral solution, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, XELJANZ 5 mg film-coated tablets, ORENCIA 87.5 mg solution

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  14. IMJUDO 20 mg/ml concentrate for solution for infusion., PACLITAXEL SANDOZ 6 mg/ml, solution à diluer pour perfusion, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CARBOPLATINE KABI 10 mg/ml, solution à diluer pour perfusion, IMFINZI 50 mg/mL concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatine Accord 1 mg/ml concentraat voor op

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Synchronous oligometastatic non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  15. IRINOTECAN HYDROCHLORIDE, CAPECITABINE, OXALIPLATIN, CAPECITABINE, CALCIUM FOLINATE, FLUOROURACIL

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Rectum cancer

    phase 3 small molecule active

    1 trial

  16. IRINOTECAN, REGORAFENIB, Stivarga 40 mg film-coated tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  17. Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung, Calciumfolinat Sandoz 10 mg/ml – Injektions-/Infusionslösung, SANIFOLIN polvere per soluzione iniettabile, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Paclitaxel Accord 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Cyramza 10 mg/ml c

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay

    phase 3 small molecule active

    1 trial

  18. Kerendia 10 mg film coated tablets, Placebo coated tablet 002 to bay 948862 coated tablet, Kerendia 20 mg film-coated tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  19. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  20. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  21. Levetiracetam NORMON 250 mg comprimidos recubiertos con película EFG, PLACEBO LEVETIRACETAM 250 mg, Levetiracetam NORMON 500 mg comprimidos recubiertos con película EFG, PLACEBO LEVETIRACETAM 500 mg

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Down syndrome, Alzheimer's Disease

    phase 3 small molecule active

    1 trial

  22. Lokelma 5 g powder for oral suspension, Lokelma 10 g powder for oral suspension

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Hyperkalemia in patients with chronic kidney disease

    phase 3 small molecule active

    1 trial

  23. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases

    phase 3 small molecule active

    1 trial

  24. Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Unresectable locally advanced and/or metastatic soft-tissue sarcoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources